PharmiWeb14h
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)[1] and OXB,[2] today announce the start of LENTICLAIRTM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...
Gene Therapy: Revolutionizing Medicine By Tackling Diseases At Their Genetic Roots
Gene therapy represents a paradigm shift in modern medicine, offering unprecedented opportunities to combat diseases at their ...
Yahoo Finance16d
Appointment of Joint Corporate Broker and Joint Financial Adviser
One of the original pioneers in cell and gene therapy, OXB has more than 25 years of experience in viral vectors ... expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other ...
Taiwan News16d
Appointment of Joint Corporate Broker and Joint Financial Adviser
Oxford, UK – 5 February 2025: OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces the appointment of Jefferies International Limited ("Jefferies") as its Joint ...
BioSpace10d
U.S. Viral Vector And Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report by 2034
This makes them ideal for treating genetic disorders and chronic diseases. Unlike AAV, which provides episomal (non-integrating) gene expression, lentiviral vectors are more suitable for therapies ...